Eocene Ltd.
EOCNHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeEocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The $3.2M market capitalization puts EOCN squarely in micro-cap range for its industry. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
Market Cap
$3.2M
Beta
0.66
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-15.21
EPS (Fwd)
—
ROE
-68.2%
ROA
-30.2%
Cash
$11.2M
Total Debt
$129,000
Free CF
-$5.3M
52W Change
-72.5%
Annual Financials
Cash vs Debt
Where EOCN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, EOCN finished 36.24% below its 150-day moving average ($4.47) and 40.00% below its 200-day moving average ($4.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EOCN overbought or oversold?
At the October 20, 2026 close, EOCN's RSI(14) was 29.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $11.2M in cash comfortably exceeding the $129K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$5.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -68.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.66 suggests EOCN is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Eocene Ltd.'s trajectory.